Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. filed this Form 8-K on August 13, 2013, to report financial results for the quarter ended June 30, 2013. The filing incorporates by reference a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1) which is referenced but not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
- Conference Call: Management hosted a conference call on August 13, 2013, to review financial results and provide updates on business matters.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions, identified by terms such as "believe," "expect," and "anticipate."
- Risk Factors: The document references risks detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including ordinary business operations and general economic conditions.
- Legal Disclaimer: Information furnished in this Item 2.02 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the attached Press Release (Exhibit 99.1).
- Review the cash position and burn rate details not present in this summary text.
- Confirm the status of clinical trials and regulatory milestones discussed during the August 13, 2013 conference call.
- Examine the Risk Factors section of the 2012 Form 10-K for updated contingencies.